Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 235,737,659 papers from all fields of science
Search
Sign In
Create Free Account
AS 703026
Known as:
AS-703026
, AS703026
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
pimasertib
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Abstract 2676: The MEK-inhibitor pimasertib is synergistic with PI3K-delta and BTK inhibitors in lymphoma models
E. Gaudio
,
C. Tarantelli
,
+9 authors
F. Bertoni
2015
Corpus ID: 78466360
Pimasertib (AS-703026) is a potent and highly selective ATP noncompetitive MEK1/2 inhibitor that has shown anti-tumor activity in…
Expand
2012
2012
Abstract 895: Quantitative drug sensitivity and resistance testing (DSRT) of primary ex vivo AML blasts highlights mTOR and MEK as potential key molecular driver signals of therapeutic significance
T. Pemovska
,
Evgeny Kylesskiy
,
+21 authors
K. Wennerberg
2012
Corpus ID: 70824727
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Identification of signaling pathways that are…
Expand
2011
2011
Resistant to EGFR Monoclonal Antibody Therapy Mutated Colorectal Cancer That Is KRAS Therapies for MEK1/2 Inhibitors AS703026 and AZD6244 May Be Potential
Juyong Yoon
,
K. Koo
,
Kang‐Yell Choi
2011
Corpus ID: 18173612
Epidermal growth factor receptor (EGFR) monoclonal antibodies (mAb) are used widely to treat metastatic colorectal cancer (mCRC…
Expand
2011
2011
Abstract 5470: Potent MEK inhibitor CIP-137401: Preclinical studies
U. Khire
,
A. Bhargava
,
B. Hart
,
M. Chordia
2011
Corpus ID: 71508404
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL In recent years there is a lot of interest in both pre…
Expand